Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
 All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library

 

 

 
MASAC Document #150- MASAC Recommendations on the Use of Blood Products during P
 

MASAC Document #150

MASAC Recommendations on the Use of Blood Products during Pregnancy and Testing for Parvovirus B19

The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on November 8, 2003, and adopted by the NHF Board of Directors on November 9, 2003.

View Printer-Friendly PDF Version >>

Parvovirus B19 infection during pregnancy may cause fetal anemia, hydrops fetalis, and fetal demise. Infection during the third trimester can induce severe congenital hypoplastic anemia in the infant. Parvovirus B19 may be transmitted by blood components such as cryoprecipitate and fresh frozen plasma. However, it is not expected to be transmitted by currently available clotting factor concentrates that have had NAT testing plus several viral attenuation methods applied.

Therefore, MASAC recommends that pregnant women with congenital bleeding disorders expected to be responsive to clotting factor concentrates who require treatment or prophylaxis for bleeding should be treated with those clotting factor concentrates rather than with cryoprecipitate or fresh frozen plasma. Additionally, MASAC recommends that, when clotting factor products are utilized for pregnant women with bleeding disorders, baseline pre-infusion testing for Parvovirus B19 should be done to include immune titers and PCR testing; these should be repeated post-infusion. Ideally this testing should be performed through a CDC testing program such as the UDC. Women who seroconvert and their physicians should be informed of this fact as expeditiously as possible.